News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingView Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article reports an SEC filing by EUDA Health Holdings Ltd (NASDAQ: EUDA) indicating the effectiveness of an F-3 shelf registration statement on August 10, 2026. The filing was accepted by the SEC EDGAR system on August 11, 2026. The article also provides recent โฆ
The article provides an earnings forecast for EUDA Health Holdings Ltd (EUDA), highlighting its current earnings forecast score of 8.00 and an average price target of $6.00. Based on one analyst's rating, the stock is currently recommended as a "Buy" with a significant upside โฆ
This article provides current stock news for EUDA Health Holdings Ltd (EUDA), including its recent trading performance with a 11.73% increase. It also lists market capitalization and indicates that more news, earnings, and analyst ratings are expected soon. The page serves as a hub โฆ
TradingKey provides a comprehensive stock analysis for EUDA Health Holdings Ltd (EUDA), highlighting its healthy fundamentals and significant growth potential. The company is currently considered fairly valued within the Healthcare Equipment & Supplies industry, despite very low institutional ownership. Analysts have issued "Buy" ratings โฆ
EUDA Health Holdings Limited has filed an amended Form F-3 to register the resale of up to 947,963 ordinary shares by existing shareholders. The company, which has shifted its focus from medical services to property management and wellness distribution, reported recurring losses and material โฆ
EUDA Health Holdings Limited has detailed its planned collaboration under a non-binding Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. The initiative aims to combine GO POSBโs induced pluripotent stem cell platform and universal tumor organoid bank โฆ
This article provides a valuation analysis of EUDA Health Holdings Ltd (EUDA), noting its current valuation score of 9.04 and a P/E ratio of -13.17. It highlights that EUDA ranks 42 out of 199 in the Healthcare Equipment & Supplies industry. The article also โฆ
EUDA Health Holdings Limited (NASDAQ:EUDA) has provided further information regarding its cell therapy program, which stems from a memorandum of understanding signed on July 15, 2026. This collaboration, involving GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd., aims to develop cell โฆ
EUDA Health Holdings Limited has announced a collaboration with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. to advance an integrated iPSC cell therapy program for oncology and wellness. The partnership aims to develop, manufacture, and commercialize next-generation off-the-shelf cell therapies โฆ
EUDA Health (NASDAQ: EUDA) has outlined an integrated cell therapy program based on a non-binding Memorandum of Understanding (MOU) signed with GO POSB Organoids and Shenzhen Innovation Immunotechnology (SIIT). The collaboration aims to develop off-the-shelf cell therapies for wellness and oncology by combining GO โฆ
EUDA Health Holdings Ltd (EUDA) has received a financial score of 4.15, placing it 199 out of 199 in the Healthcare Equipment & Supplies industry. The company's financial status is stable, but its operating efficiency is low, with a significant year-over-year decrease in revenue โฆ
This article provides a risk assessment for EUDA Health Holdings Ltd (EUDA), detailing its volatility, financial risk, and investment risk. The company has a beta value of 0.64, indicating lower volatility compared to the S&P 500. Its current risk assessment score is 1.17, placing โฆ
The article provides an overview of EUDA Health Holdings Ltd (EUDA) stock performance and its institutional confidence score. The institutional shareholding data shows key holders and changes in their positions, with Watermark Developments Ltd holding the largest number of shares. The company's stock closed โฆ
EUDA Health Holdings has signed a tri-party Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. to develop, manufacture, and commercialize iPSC-based, off-the-shelf oncology cell therapies. This collaboration aims to enhance EUDA's wellness portfolio and distribution in โฆ
EUDA Health Holdings Limited has signed a tri-party Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. The collaboration aims to advance next-generation induced pluripotent stem cell (iPSC) therapies, including NK-TCR cell therapies, for cancer treatment and wellness. โฆ
Euda Health Holdings Limited, Go POSB Organoids Pte Ltd, and Shenzhen Innovation Immunotechnology Co. Ltd. have signed a tri-party Memorandum of Understanding (MOU). This collaboration aims to develop, manufacture, and commercialize next-generation off-the-shelf oncology cell therapies derived from induced pluripotent stem cells (iPSC) for โฆ
EUDA Health Holdings Limited has signed a non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. This agreement aims to foster collaboration on the development, manufacturing, and commercialization of oncology cell therapies derived from induced pluripotent โฆ
EUDA Health Holdings has signed a Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology
EUDA Health (NASDAQ: EUDA) has signed a tri-party Memorandum of Understanding (MOU) with GO POSB Organoids and Shenzhen Innovation Immunotechnology (SIIT). The collaboration aims to develop, manufacture, and commercialize next-generation off-the-shelf oncology cell therapies derived from induced pluripotent stem cells (iPSC) for cancer treatment โฆ
This article provides an overview of EUDA Health Holdings Ltd (EUDA)'s dividend and stock split history. It indicates that no dividends have been distributed in the past five years, but it details a significant 20-for-1 merger type stock split that occurred on March 19, โฆ
This article provides a detailed financial overview of EUDA Health Holdings Ltd (EUDA), presenting key financial statements such as the income statement, balance sheet, and cash flow statement. It highlights the company's latest earnings report for FY2025, including revenue, EPS, and various financial indicators. โฆ
This article provides the quarterly and annual income statements for EUDA Health Holdings Ltd (EUDA), offering a detailed financial overview. It presents key metrics such as total revenue, operating expenses, net income, and earnings per share across various fiscal periods. The article also includes โฆ
EUDA Health Holdings Ltd (EUDA) is currently trading at $14.99, up 6.57%. The company, a health technology firm operating a Southeast Asian digital healthcare ecosystem, has seen its revenue grow significantly over the past three years. Analysts have a "Buy" rating for EUDA, with โฆ
This article provides an overview of EUDA Health Holdings Ltd (EUDA) shareholder structure, detailing major individual, corporate, and institutional holders and their respective proportions. It also presents a historical look at institutional shareholding data from Q4 2023 to Q1 2026, alongside recent shareholder activity โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States